CHA Biotech announced that it had hired Lee Hyun-jung, former CEO of Samyang Biopharm USA, as president. President Lee oversees the research and development division of CHA Biotech and CHA Bio Group.
After graduating from Yonsei University College of Medicine, President Lee Hyun-jung completed her residency training at Yonsei University Medical Center Severance Hospital and obtained qualifications as an obstetrician-gynecologist. He received a master’s degree in healthcare management from Harvard University, USA.
Additionally, President Lee is a clinical development expert with 20 years of experience developing new drugs in the global market. He worked as the global general manager of clinical development of anticancer drugs at global pharmaceutical companies such as Pfizer in Korea, Eli Lilly headquarters in the U.S., and Baxalta and Shire (now Takeda). From 2016 to 2021, he served as Chief Strategy Officer and Chief Medical Officer of Samyang Biopharm and President of Samyang Biopharm USA. In 2020, he was selected as one of the ‘100 People in the Life Science Industry of 2020’ published by PharmaVOICE, an American pharmaceutical monthly magazine.
CHA Biotech said, “We expect President Lee Hyun-jung to contribute to accelerating research and development of the cell therapy pipeline and promoting global business beyond Korea.”
Source: Pangyo Techno Valley Official Newsroom
→ Go to ‘Asian Innovation Hub Pangyo Techno Valley 2022’ news